Heart disease is the leading cause of death for women in the United States, yet many physicians wait until cholesterol levels become dangerously high before intervening. This approach can miss the silent cardiovascular shifts that often start years earlier, during the perimenopausal transition.

Why perimenopause matters for the heart

Medical experts now view perimenopause as a critical “window of opportunity” for protecting heart health. A 2026 analysis published in the Journal of the American Heart Association found that perimenopausal women were twice as likely to have lower measures of cardiovascular health compared with women who maintain regular menstrual cycles.

Before menopause, estrogen performs several heart‑protective functions: it helps clear cholesterol from the bloodstream, keeps blood vessels flexible, supports insulin sensitivity, and regulates inflammation. When estrogen levels begin to fluctuate in perimenopause and then drop sharply after menopause, these protections erode, even if a standard cholesterol panel still reads within normal limits.

Changes in cholesterol and blood vessels

High‑density lipoprotein (HDL) cholesterol—often called the “good” cholesterol—carries excess cholesterol to the liver for disposal. Estradiol, the primary form of estrogen, helps maintain both the quantity and effectiveness of HDL particles. As estradiol declines, HDL particles can become smaller and less efficient, even when HDL levels appear normal on a lab test.

At the same time, low‑density lipoprotein (LDL) cholesterol—the “bad” cholesterol—and ApoB, a marker of plaque‑forming particles, rise most rapidly in the year before and after menopause. The result is more harmful cholesterol and fewer effective carriers to clear it.

Blood vessels may also become stiffer, creating a more favorable environment for plaque buildup. A study of over 52,000 women linked estrogen loss during menopause with increased arterial stiffness.

Shifts in body fat and blood sugar

Estrogen helps direct fat storage to the hips and thighs. As estrogen declines, fat tends to accumulate around the midsection, where it poses greater risk to the heart. The 2021 Study of Women’s Health Across the Nation (SWAN) reported that visceral fat—deeply embedded fat surrounding internal organs—rises from roughly 5‑8% of total body fat before menopause to 15‑20% afterward. This increase is associated with greater arterial plaque in the brain‑supplying vessels, raising the risk of heart disease and stroke.

Estrogen also supports insulin sensitivity. Lower estrogen levels can increase insulin resistance, contributing to higher blood sugar, elevated blood pressure, and greater cardiovascular risk.

Blood pressure, inflammation, and clotting

Estrogen’s anti‑inflammatory effects help keep blood vessels healthy and blood pressure stable. When estrogen wanes, both inflammation and blood pressure may rise. Inflammation thickens and stiffens arteries, while higher pressure forces the heart to work harder—both factors increase the likelihood of heart attack and stroke.

Estrogen also moderates platelet activity, reducing the tendency for blood clots to form. A decline can make the clotting system more reactive, allowing clots to develop on arterial plaque and potentially block blood flow to the heart or brain.

These physiological shifts help explain why stroke rates double for women between their late forties and early sixties.

What women can do now

A standard cholesterol panel is a useful starting point, but it may not capture the full picture. Women should discuss with their physicians whether additional testing—such as measuring arterial inflammation, ApoB levels, or liver function—might be appropriate.

Hormone replacement therapy (HRT) can restore estrogen to levels that significantly reduce many of the factors driving heart disease, especially when started at the right time and under proper medical supervision. The cardiovascular benefit‑risk profile is most favorable when HRT begins before age 60 or within ten years of menopause. In the large‑scale Women’s Health Initiative study, women aged 50‑59 who received estrogen‑only HRT experienced a 40% lower risk of heart attack compared with those taking a placebo.

After age 60, the risk‑benefit balance shifts, and individualized assessment becomes essential. The formulation of HRT matters: oral estrogen passes through the liver and can raise triglycerides and clotting factors in some women, while transdermal estrogen—delivered via patch, gel, or cream—bypasses the liver and may offer a more favorable clotting profile. Whether a woman needs estrogen alone or combined with progesterone depends on her health history and whether she has a uterus.

Lifestyle measures that support heart health

Hormones are only one piece of the puzzle. Strength training, regular aerobic activity, adequate sleep, and a balanced diet all directly influence ApoB, blood pressure, and insulin resistance—the same markers that drive cardiovascular risk.

Women should aim for a diet rich in whole foods, fiber, lean protein, and healthy fats while limiting processed sugars and excessive sodium. Maintaining a healthy weight, especially reducing abdominal fat, further supports vascular health.

Regular check‑ups, open conversations with healthcare providers, and proactive monitoring of heart‑related markers can empower women to navigate the perimenopausal transition with confidence and protect their long‑term heart health.

Original reporting: KTVZ (Central Oregon) — read the source article.